University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

2016

Metabolic control in patients with type 2 diabetes mellitus in a
public hospital in Peru: a cross-sectional study in a low-middle
income country
Irma Huayanay
The University of Texas Rio Grande Valley

Felix Guerra-Castañon
Maria Lazo-Porras
Ana Castaneda-Guarderas
Nimmy Josephine Thomas

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Diseases Commons

Recommended Citation
Huayanay-Espinoza IE, Guerra-Castañon F, Lazo-Porras M, Castaneda-Guarderas A, Thomas NJ, GarciaGuarniz A, Valdivia-Bustamante AA, Málaga G. 2016. Metabolic control in patients with type 2 diabetes
mellitus in a public hospital in Peru: a cross-sectional study in a low-middle income country. PeerJ
4:e2577 https://doi.org/10.7717/peerj.2577

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator
of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu,
william.flores01@utrgv.edu.

Authors
Irma Huayanay, Felix Guerra-Castañon, Maria Lazo-Porras, Ana Castaneda-Guarderas, Nimmy Josephine
Thomas, Ana-Lucia Garcia-Guarniz, Augusto A. Valdivia Bustamante, and German Malaga

This article is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/som_pub/215

Metabolic control in patients with type
2 diabetes mellitus in a public hospital
in Peru: a cross-sectional study in a lowmiddle income country
Irma Elizabeth Huayanay-Espinoza1 , Felix Guerra-Castañon1 ,
María Lazo-Porras1 ,2 , Ana Castaneda-Guarderas1 ,2 ,3 ,4 ,
Nimmy Josephine Thomas5 , Ana-Lucia Garcia-Guarniz1 ,
Augusto A. Valdivia-Bustamante1 and Germán Málaga1 ,2 ,6 ,7
1

Unidad de Conocimiento y Evidencia (CONEVID), Universidad Peruana Cayetano Heredia, Lima, Peru
CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru
3
Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN, United States
4
Emergency Medicine, Mayo Clinic, Rochester, MN, United States
5
Rollins School of Public Health, Emory University, Atlanta, GA, United States
6
Faculty of Medicine ‘‘Alberto Hurtado,’’ Universidad Peruana Cayetano Heredia, Lima, Peru
7
Department of Internal Medicine, Hospital Cayetano Heredia, Lima, Peru
2

ABSTRACT

Submitted 6 May 2016
Accepted 16 September 2016
Published 13 October 2016
Corresponding author
Irma Elizabeth Huayanay-Espinoza,
irma.huayanay@upch.pe
Academic editor
Teresa Seccia
Additional Information and
Declarations can be found on
page 12

Objective. The objective of this study was to assess patients’ achievement of ADA
(American Diabetes Association) guideline recommendations for glycosylated
hemoglobin, lipid profile, and blood pressure in a type 2 diabetes mellitus (T2DM)
outpatient clinic in a low-middle income country (LMIC) setting.
Methods. This is a descriptive cross-sectional study with 123 ambulatory T2DM patients who are being treated at a public hospital in Lima, Peru. Data was gathered via
standardized interviews, clinical surveys, and anthropomorphic measurements for
each patient. Blood samples were drawn in fasting state for measures of glucose, glycosylated hemoglobin (HbA1c), and lipid profile. Laboratory parameters and blood
pressure were evaluated according to ADA recommendations.
Results. Of the 123 patients, 81 were women and the mean age was 61.8 years.
Glycemic control was abnormal in 82 (68.33%) participants, and 45 (37.50%) were
unable to control their blood pressure. Lipid profile was abnormal in 73 (60.83%)
participants. Only nine (7.50%) participants fulfilled ADA recommendations for
glycemic, blood pressure, and lipid control.
Conclusions. Amongst individuals with type 2 diabetes, there was poor attainment
of the ADA recommendations (HbA1c, blood pressure and LDL-cholesterol) for ambulatory T2DM patients. Interventions are urgently needed in order to prevent longterm diabetic complications.
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INTRODUCTION
Type 2 Diabetes Mellitus (T2DM) is a chronic disease with a growing prevalence worldwide (Fauci et al., 2009; Aschner et al., 2014). In 2014, the International Diabetes Federation (IDF) estimated that the disease prevalence in South/Central America and Peru
was 8% and 6.1%, respectively (Aschner et al., 2014) . However, Seclen et al. (2015) found
a slightly higher national prevalence of 7% in Peru and 8.4% in metropolitan Lima—a
prevalence that has almost doubled in the last seven years.
Metabolic control in T2DM is a critical component in diabetes care. Without wellestablished metabolic control, complications can arise increasing mortality rates and
lowering quality of life—this represents an important burden of disease for low-middle
income countries (LMICs) (Aschner et al., 2014; Huang et al., 2014). Additionally,
several comorbidities are related to poor metabolic control including dyslipidemia,
hypertension, and obesity, increasing the risk of long-term macro and micro-vascular
complications (Colosia, Palencia & Khan, 2013). It has been reported that more than
80% of deaths associated with T2DM in LMICs occur due to poor metabolic control
(World health Organization, 2014). A multicenter study performed in the US comparing
glycemic control in Hispanic/Latino, non-Hispanic white, and non-Hispanic black
populations found that the non-Hispanic black and white populations had better
glycemic control when compared to their Hispanic/Latino counterparts (Schneiderman
et al., 2014). They reported that Hispanic/Latino populations had the lowest percentage
of participants with good glycemic control among the three groups, 47.3% compared to
52.9% and 52.6% in non-Hispanic white and black populations, respectively. In another
multicenter cross-sectional study conducted in nine countries in Latin America (Lopez
Stewart et al., 2007) ,the overall poor glycemic control (HbA1c ≥ 7% (53 mmol/mol))
was 56.8% while Peru had the worst numbers among all with 70% having poor glycemic
control. Another study conducted within an elderly population in Costa Rica reported
that 37% had poor metabolic control (HbA1c ≥ 7% (53 mmol/mol)), 78% had a systolic
blood pressure ≥ 130 mmHg, 66% had a diastolic blood pressure ≥ 80 mmHg, and 78%
had a LDL-cholesterol ≥ 100 mg/dl (Brenes-Camacho & Rosero-Bixby, 2008).
Long term care of T2DM patients represents a grand challenge for health care
systems around the world (Aschner et al., 2014). In order to evaluate the quality of
T2DM management, it has been widely agreed that the proper management and
control of glycosylated hemoglobin (HbA1c), LDL-cholesterol and blood pressure
are the key to prevent complications (American diabetes Association, 2016). These can
also be used to measure the quality of diabetic healthcare in different health systems
(American diabetes Association, 2016). Moreover, it is well-known that factors associated
with a healthy lifestyle (Westman et al., 2008), regular physical activity (three times a
week), and adherence to treatment can positively influence the course of the disease
(American diabetes Association, 2016). There are several factors such as ethnicity and
depression that have not been completely explored. With regards to depression, some
studies have found a 15–20% correlation between T2DM and depression incidence,
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although a significant association has not yet been found (Gonzales et al., 2007; Zuberi,
Syed & Bhatti, 2011; Stanković, 2011).
In South America, particularly in Peru, there are few studies that evaluate demographic
and clinical characteristics associated with glycemic control, blood pressure, and lipid
profile in a clinical setting (Stanković, 2011). Such a study could help to identify the main
factors that affect the course of T2DM, thus letting physicians and patients work on
modifying strategies to improve the patient’s prognosis.
The objectives of this study were to: (1) explore the quality of T2DM control through
achievement of the American Diabetes Association (ADA) recommendations, and (2)
determine whether demographic characteristics, lifestyle choices, and clinical parameters
of patients in a public hospital in Peru have an impact on the quality of control of
T2DM.

MATERIALS AND METHODS
Study design and participants
We conducted a cross-sectional study in which participants diagnosed with T2DM
were recruited between March and July 2012 from the Endocrinology clinic of Hospital
Cayetano Heredia in Lima, Peru. This is a university hospital located in San Martin
de Porres, a low-income district north of the Peruvian capital (Acevedo, Cisneros &
Curaca, 2014).
The recruitment strategy was convenience sampling, with patients recruited while
they were waiting for their routine clinical encounter. The inclusion criteria included
a diagnosis of T2DM for more than 12 months from the recruitment day, ≥18 years
old, and at least one visit to the Endocrinology clinic in the previous year. Patients
were excluded if they were diagnosed with secondary or gestational diabetes, chronic
non-cardio-metabolic diseases (systemic lupus erythematous, rheumatoid arthritis,
chronic obstructive pulmonary disease), or any mental illness or incapability. Patients
who had presented with major complications of T2DM (stroke, coronary heart disease,
hyperglycemic/hypoglycemic crisis, diabetic foot) in the previous year and those who had
been hospitalized within the previous six months were also excluded due to the decline in
social, physical and psychological functionality after these major complications and their
added risk factors for mortality (Simpson & Pilote, 2005; Resnick et al., 2004).

Assessment and outcome measures
The participants were assessed using a standardized interview and an evaluation of their
medical records, using the International Physical Activity Questionnaire (IPAQ), the
Scale of Adherence to Diabetes Mellitus Type 2 Treatment (Escala de Adherencia al
Tratamiento de la Diabetes Mellitus tipo II—EATDM-III), and Center for Epidemiological Studies-Depression (CES-D) scale (Handelsman et al., 2015; IPAQ Research Committee,
2015; Villalobos-Pérez et al., 2006). For laboratory measurements, a venous sample of
10cc was taken from the arm in the morning after a minimum 8 h fast from which fasting
glucose, glycosylated hemoglobin, and lipid profile were measured.
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To define ‘‘poor metabolic control,’’ the American Diabetes Association (ADA)
recommendations were used: poor glycemic control (HbA1c ≥ 7% (53 mmol/mol)),
poor controlled blood pressure (BP ≥ 140/90 mmHg), and poor controlled LDLcholesterol (LDL ≥ 100 mg/dL) (American diabetes Association, 2016). Also, we include
an additional analysis using HbA1c ≥8%, because some studies have recommended
individualized treatment for each patient and propose the use of a less stringent parameter
(American diabetes Association, 2016; Handelsman et al., 2015).
Demographic variables were also collected including gender, age (<65 years old or
≥65 years old), and marital status (in a couple: married, cohabiting, or single: not in a
relationship, widowed, divorced). The clinical data collected included: years of disease
(1–10 years or ≥10 years); treatment (none, oral anti-diabetic, insulin, both); body mass
index (BMI), and chronic diabetic complications defined as microvascular (retinopathy,
nephropathy, and neuropathy) and macrovascular (coronary heart disease, stroke, and
peripheral artery disease).
Participant’s activity levels were assessed using the IPAQ with three categories: inactive,
minimally active, and HEPA active (health enhancing physical activity) (IPAQ Research
Committee, 2015) (Table S1).
The scale used to measure adherence was EATDM-III, which has previously been used
in Costa Rica (Villalobos-Pérez et al., 2006). This scale has seven categories including
family support, communal organization, physical exercise, medical control, hygiene
and self-care, diet, and appreciation of the physical condition. The questionnaire has
55 questions and each one has a score between 0 and 4. The total obtained is divided by
the maximum score points (220 points) and then multiplied by 100%. Scores near 100%
signify more adherence (Villalobos-Pérez et al., 2006).
Depression was evaluated using the CES-D. A score greater than or equal to 24
is considered positive for the presence of depression. The scale was previously validated for the Peruvian population with a sensitivity of 91.4% and specificity of 96.7%
(Ruiz-Grosso et al., 2012).

Sample size and calculation
The sample size of 123 participants was based on the DEAL study (Diabetes en America
Latina) (Lopez Stewart et al., 2007), using a prevalence of poor glycemic control of
56.7% with a confidence level of 95% (Z = 1.96). Calculated power for depression was
28% (Crispin, Robles & Bernabe, 2015).

Statistical analysis
Statistical analyses were performed using Stata 12.0. Demographic variables (age, gender,
marital status), clinical criteria (disease duration, treatment, complications), lifestyle
factors (IPAQ, EATDM-III), and comorbidity (depression) variables were compared
against glycosylated hemoglobin looking for significant associations. Chi-square was
used for comparison of qualitative variables and t -test for comparison of a quantitative
vs qualitative variable.
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Multivariate models were generated using Poisson regression reporting prevalence
ratios (PR) and 95% Confidence intervals (CI). Crude and adjusted analyses were performed for the three models generated to evaluate the independent association between
(i) glycemic control, (ii) blood pressure, and (iii) LDL-cholesterol with demographic,
clinical, lifestyle, and comorbidity variables.

Ethics
The study protocol was approved by the Ethical Review Board of the Universidad Peruana
Cayetano Heredia and Ethical Committee of Hospital Cayetano Heredia. Written
informed consent was obtained from all patients.

RESULTS
The recruitment rate was 89.78% (123/137). Of the 123 patients participating in the
study, blood samples were received from 120 patients. Most participants (65.85%)
were female and the mean age was 61.84 ± 11.10. In addition, majority of the patients
(63.41%) were in a relationship (i.e., married, living together). Mean HbA1c was 8.2% ±
2.19 (66 mmol/mol), mean LDL (mg/dL) was 107.61 ± 39.66 and mean blood pressure
was 133.26 ± 19.03/ 75.64 ± 10.84 mmHg. The prevalence of uncontrolled HbA1c was
68.33%, uncontrolled LDL-cholesterol was 60.83%, and uncontrolled blood pressure
was 37.50%. With regards to comorbidities, 37.40% had hypertension and 33.33% had
depression. Other characteristics of the population studied are shown in Table 1. Using
a cutoff point of HbA1c of 7%, only 9 (7.5%) patients met all the standards of the ADA
recommendations for T2DM, but when a cutoff point HbA1c of 8% was utilized, 17
patients met all standards (14.2%).
The patients diagnosed with diabetes for 1–10 years had better glycemic control
compared to those who had had a diabetes diagnosis for ≥10 years (42.37% vs. 21.31%,
p = 0.013). Good glycemic control was present in 21.92% patients younger than 65 years
old and in 46.81% of those older than 65 years (p = 0.004). Those patients who were not
on pharmacological treatment had better glycemic control than the patients who required
pharmacologic therapy (p < 0.001). A detailed comparison between each variable and
glycemic control is shown in Table 2.
In the adjusted model, a negative association with poor glycemic control (HbA1c
≥ 7%) was found in patients who were 65 years or older when compared to younger
participants ( PR = 0.59 ; 95% CI [0.44–0.78]) and with patients who were in a relationship compared to single patients ( PR = 0.74 ; 95% CI [0.59–0.92]). Also, a positive
association with poor glycemic control was found with more than 10 years of disease
(PR = 1.43 ; 95% CI [1.05–1.71]), oral antidiabetic (OAD) use plus insulin treatment
(PR = 2.57 ; 95% CI [1.05–6.32]), and minimal physical activity ( PR = 1.63 , 95% CI
[1.23–2.15]) in the crude and adjusted model in comparison with their counterparts.
BMI was included in the adjusted Poisson regression model, but there was no association
found with glycemic control, LDL-cholesterol, or blood pressure. We did not find an
association between LDL-cholesterol or blood pressure and demographic, clinical, lifestyle
(IPAQ, EATDM-III) and comorbidity variables (Table 3).
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Table 1 Characteristics of the study population (N = 123).
Variables

N (%)

Age mean ± SD

61.84 (±11.10)

Age groups (%)
Age < 65 years

73 (59.35%)

Age ≥ 65 years

50 (40.65%)

Gender (%)
Female

81 (65.85%)

Male

42 (34.15%)

Marital Status (%)
Single

19 (15.45%)

Married

53 (49.09%)

Living together

25 (20.33%)

Divorced

7 (5.69%)

Widowed

19 (15.45%)

Years of disease (%)
1–10 years

61 (49.59%)

≥10 years

62 (50.41%)

Treatment (%)
No pharmacological treatment

10 (8.13%)

OAD

74 (60.16%)

Insulin

8 (6.50%)

OAD plus insulin

31 (25.20%)

HbA1c (%)

8.23 ± 2.19

HbA1c (%) by ranges
HbA1c < 7%

43 (35.83%)

HbA1c = 7–8%

23 (19.17%)

HbA1c = 8–9%

22 (18.33%)

HbA1c = 9–10%

9 (7.5%)

HbA1c > 10%

23 (19.17%)

LDL(mg/dL), mean ± SD

107.61 ± 39.66

Blood pressure (mmHg), mean (%)
Without hypertension

77 (62.60%)

With hypertension

46 (37.40%)

BMI, mean ± SD

28.5 ± 4.71

IPAQ
HEPA active

67 (56.30%)

Minimally active

25 (21.01%)

Inactive

27 (22.69%)

EATDM-III

56.69 ± 11.28

Depression
Yes

41 (33.33%)

No

82 (66.67%)

Notes.
HbA1c, Glycosylated hemoglobin; BMI, Body mass index; IPAQ, International Physical Activity Questionnaire; OAD,
Oral antidiabetics; EATDM-III, Escala de adherencia al tratamiento de la diabetes mellitus tipo II.
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Table 2 Characteristics of the study population according to glycemic control.
Good glycemic control
(n = 38)

Poor glycemic control
(n = 82)

64.80 ± 10.4

60.47 ± 11.2

p- value

Demographics
Age ± SD
Age per range(%)

0.004

Age < 65 years

16 (21.92%)

57 (78.08%)

Age ≥ 65 years

22 (46.81%)

25 (53.19%)

Female

24 (30.38%)

55 (69.62%)

Male

14 (34.15%)

27 (65.85%)

Without couple

10 (23.26%)

33 (76.74%)

With couple

28 (36.36%)

49 (63.64%)

27.7 ± 4.52

28.87 ± 4.78

1–10 years

25 (42.37%)

34 (57.63%)

≥10 years

13 (21.31%)

48 (78.59%)

No pharmacological treatment

7 (70%)

3 (30%)

OAD

28 (38.89%)

44 (61.11%)

Insulin

2 (25%)

6 (75%)

OAD plus Insulin

1 (3.33%)

29 (96.67%)

0.674

Gender (%)

0.139

Marital status (%)

Clinical
BMI ± SD
Years of disease (%)

0.013

Treatment(%)

<0.001

Complications (%)
Microvascular

0.593

Yes

12 (28.57%)

30 (71.43%)

No

26 (33.33%)

52 (66.67%)

Macrovascular

0.597

Yes

7 (36.84%)

12 (63.16%)

No

31 (30.69%)

70 (69.319%)

HEPA active

25 (37.31%)

42 (62.69%)

Minimally active

4 (16%)

21 (84%)

Inactive

8 (29.63%)

19 (70.37%)

EATDM-III ± SD

57.26 ± 11.81

56.42 ± 11.10

Lifestyle
0.143

IPAQ (%)

Comorbidities
0.684

Depression (%)
Yes

12 (29.27%)

29 (70.73%)

No

26 (32.91%)

53 (67.09%)

Notes.
BMI, Body mass index; IPAQ, International Physical Activity Questionnaire; OAD, Oral antidiabetics; EATDM-III, Escala de adherencia al tratamiento de la diabetes mellitus tipo II.
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Table 3 Factors associated with glycemic control, LDL cholesterol and blood pressure.
Glycemic control

LDL cholesterol

Blood pressure

Crude model
PR (95% IC)

Multivariable
modela
PR(95% IC)

Crude model
PR (95% IC)

Multivariable
modela
PR ( 95% IC)

Crude model
PR (95% IC)

Multivariable
modelb
PR (95% IC)

Female

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

Male

0.95 (0.73–1.23)

1.07 (0.84–1.36)

1.00 (0.74–1.36)

1.01 (0.72–1.42)

1.06 (0.66–1.72)

1.01 (0.62–1.64)

Gender

Age
Age < 65 years

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

Age ≥ 65 years

0.68(0.51–0.92)

0.59(0.44–0.78)

0.91 (0.67–1.24)

0.98 (0.70–1.38)

1.36 (0.86–2.15)

1.61 (0.99–2.60)

Marital status
Without couple

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

With couple

0.83 (0.65–1.05)

0.74 (0.59–0.92)

0.95 (0.71–1.28)

1.03 (0.74–1.43)

1.12 (0.68–1.84)

1.32 (0.80–2.19)

1–10 years

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

≥10 years

1.37 (1.06–1.76)

1.34 (1.05–1.71)

0.94 (0.71–1.26)

0.85 (0.62–1.17)

0.93 (0.58–1.47)

0.85 (0.53–1.34)

No pharmacological
treatment

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

–

OAD

2.04 (0.77–5.37)

1.75 (0.70–4.38)

0.97 (0.56–1.68)

0.99 (0.58–1.71)

1.01 (0.45–2.27)

–

Insulin

2.5 (0.89–7.02)

1.70 (0.62–4.65)

1.25 (0.65–2.39)

1.29 (0.65–2.56)

0.94 (0.29–3.05)

–

OAD plus insulin

3.22 (1.24–8.36)

2.57 (1.05–6.32)

1.06 (0.59–1.88)

1.13 (0.62–2.04)

0.75 (0.29–1.92)

–

No complications

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

–

At least 1 complication

0.98 (0.76–1.25)

0.80 (0.62–1.03)

1.13 (0.85–1.51)

1.23 (0.89–1.69)

0.80 (0.49–1.31)

–

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

–

Minimally active

1.34 (1.04–1.73)

1.63 (1.23–2.15)

0.89 (0.60–1.33)

0.91 (0.61–1.37)

0.86 (0.45–1.65)

–

Inactive

1.12 (0.83–1.53)

1.31 (0.98–1.75)

0.95 (0.66–1.36)

0.93 (0.64–1.34)

1.19 (0.70–2.02)

–

No

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

1 (Reference)

–

Yes

1.05 (0.82–1.36)

1.17 (0.94–1.45)

1.00 (0.74–1.36)

0.93 (0.67–1.27)

1.54 (0.98–2.42)

–

EATDM-III

1.00 (0.99–1.01)

1.00 (1.00–1.02)

1.00 (0.98–1.01)

0.99 (0.98–1.01)

0.98 (0.96–1.01)

0.98 (0.96–1.00)

Years of diasease

Treatment

Complications

IPAQ
HEPA active

Depression

Notes.
a
Adjusted model for gender, marital status, years of disease, treatment, complications, IPAQ, depression and EATDM-III.
b
Adjusted model for gender,age, marital status, years of disease and EATDM-III.
IPAQ, International Physical Activity Questionnaire; OAD, Oral antidiabetics; EATDM-III, Escala de adherencia al tratamiento de la diabetes mellitus tipo II.

DISCUSSION
Main findings and comparison with other studies
Only 7.5% of the patients achieved the levels of glycemic control in T2DM recommended
by the ADA (glycosylated hemoglobin, LDL-cholesterol and blood pressure). In Latin
America, a Colombian retrospective study with a bigger sample size got a similar result
of 6.9% (Machado-Alba, Moncada-Escobar & Gaviria, 2009). There are several differences
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between these two studies. For example, all participants in the Colombian study were
from the social security health program, suggesting they had better access to care for
controlling their blood glucose levels and follow up care compared to our patients. The
Colombian study also had a bigger sample size from a multicenter study with a follow-up
period of one year (Machado-Alba, Moncada-Escobar & Gaviria, 2009). In a twin crosssectional study performed in India with one hundred participants and three time points—
baseline, three months, and six months—HbA1c, blood pressure and LDL-cholesterol
were evaluated (Menon & Ahluwalia, 2015). Only one participant (1%) achieved the
ADA’s guidelines at three months, but at six months this number increased to three
participants achieving the recommended guidelines (3%). Due to some characteristics
of our population, mostly advanced age and comorbidities, we also considered another
cutoff point of HbA1c≤ 8% for controlled diabetes, which indicated an increase in
controlled disease from 7.5% to 14.2%. Even though there’s an increase, it is still not
enough for the achievement of ADA recommendations. Furthermore, 26.67% of patients
had HbA1c >9%; this is untenable and incompatible with a good healthcare system and
appropriate quality of attention to patients with diabetes.
Of all participants in this study, 68.33% had poor glycemic control, 37.50% had
uncontrolled blood pressure and 60.83% had an abnormal lipid profile. These are
worrisome results as achieving the ADA recommendations is pertinent in decreasing
micro-vascular and macro-vascular complications and death in T2DM patients. This is
shown in the Steno 2 study, which compared intensive treatment against conventional
treatment in primary outcomes of T2DM patients (Gaede et al., 2008). The outcomes
of this study were positive for intensive treatment having an overall-death hazard
ratio of 0.54 (95% CI [0.32–0.89]; p = 0.02), cardiovascular-death hazard ratio of
0.43 (95% CI [0.19–0.94]; p = 0.04) and cardiovascular-events hazard ratio of 0.41
(95% CI [0.25–0.67]; p < 0.001).
In a systematic review of 14 studies that involved 19 countries: 55.5% of subjects had
HbA1c > 7% (53 mmol/mol), 64.8% of subjects had blood pressure > 130/80, and 48.6%
subjects had LDL-cholesterol > 100 mg/dL (Menon & Ahluwalia, 2015). The difference
with these studies is that they were mainly conducted in high-income countries (17 out
of 19 were high income countries) (Pinchevsky et al., 2015). In the cross-sectional study
in India, they measured HbA1c, blood pressure and LDL-cholesterol at three time points
(Menon & Ahluwalia, 2015). The percentage of participants not meeting each of the ADA
recommendations at the three time points (baseline, three, and six months) were: HbA1c
> 7% (53 mmol/mol) (55%, 47%, 45%), blood pressure > 130/80 (73%, 77%, 75%), and
LDL-cholesterol (63%, 67%, 60%).
Interestingly, in our study, participants who were older than 65 and in a relationship
were able to achieve better glycemic control. Meanwhile having more than 10 years of
disease, OAD plus insulin treatment, and doing minimal physical activity was associated
with poor glycemic control. There was not a significant association between the above
analyzed variables and LDL-cholesterol or blood pressure.
Participants older than 65 were more likely to have good glycemic control (PR =
0.59; 95% CI [0.44–0.78]) than their younger counterparts. Similar results were found
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in other studies, for example in Mexico and the United States (Flores-Hernández et al.,
2015; Ali et al., 2012) , where a significant relationship between good glycemic control and
an elderly population were found. Furthermore, the ACCADEMY study group (Giorda
et al., 2015) showed that patients older than 65 achieve the glycemic goal HbA1c < 7%
(53 mmol/mol) more rapidly than their younger counterparts, with older patients achieving the recommended levels within 15 months compared to 21 months of treatment.
It has also been shown that the years of disease have a significant impact towards
glycemic control, which may be due to decreased insulin production from decreased
beta-cell function after 5–10 years of disease (Levy et al., 1998). In agreement, our
participants with a diagnosis of ≥10 years were more likely to have a poor glycemic
control. This is supported by a study conducted in Jordan (Al-Akour, Khader & Alaoul,
2011) , where those who had their diagnosis 10 or more years previously had increased
odds of developing poor glycemic control (OR = 1.53; 95% CI [1.09–2.17]). In summary,
these results strongly suggest that duration of disease has a greater impact on glycemic
control than patient age.
Another variable associated with good glycemic control was marital status. In this
study, being in a relationship was shown to have protective effects with regards to the
HbA1c goals and consequently better prognosis. This is reinforced by several studies
where they found that having a partner is associated with better adherence to treatment
(Ali et al., 2012; Thompson, Auslander & White, 2001; Harris, National & Nutrition
Examination, 2001) and decreased odds of poor glycemic control (Al-Akour, Khader &
Alaoul, 2011).
Participants with no pharmacological treatment had better glycemic control in
comparison with OAD or OAD plus insulin. Similar results were reported in the Center
for Disease Control and Prevention supplement (Ali et al., 2012). This can be explained
because use of insulin alone or insulin in combination with oral drugs is used to treat
long-standing forms of the disease, whereas management without pharmacological
treatment is used for milder form of the disease (Ali et al., 2012). Ahmad, Islahudin
& Paraidathathu (2014) demonstrated that all pharmacological treatment patterns
(monotherapy, combination of OAD, insulin and OAD plus insulin) were more likely—
in varying degrees—to have poor glycemic control. This may be associated with adverse
effects and a lack of adherence to the treatment regimen.
Association of physical activity, through IPAQ score, showed that minimal physical
activity was associated with poor glycemic control ( PR = 1.34 ; 95% CI [1.04–1.73])
compared to HEPA active patients. Similar results were found by Abdel et al., who found
a statistically significant association between patients with uncontrolled T2DM and lack of
activity (71.6% vs 28.4%, p < 0.001) (Serour et al., 2007).
According to EATDMIII scale, 56.99% patients with diabetes were adherent to nonpharmacological treatment. However, it was still beneath the rate of 66% found by Alayón
& Mosquera-Vásquez (2008) in Colombia. It should be noted that they utilized a selfadministered questionnaire SDSCA (summary of diabetes self-care activities) which does
not take into account family support or community organization (Alayón & MosqueraVásquez, 2008). Both of these factors were analyzed with the EATDM III (Villalobos-Pérez
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et al., 2006). In Table 2, we illustrate that the median for EATDMIII scale was similar for
the patients with good glycemic control and for the patients with poor glycemic control
which suggests that glycemic control and adherence might be influenced by other factors
such as knowledge of the disease (Milla, Perez & Rodriguez, 2008), disease characteristics,
environment, and intrapersonal and interpersonal factors (WHO, 2003).
Prevalence of depression in our patients with T2DM was 33.33%, which is five times
the prevalence of depression reported in the general population (6.7%) (Instituto Especializado de Salud Mental Honorio Delgado –Hideyo Noguchi, 2002). However, there was not
a significant correlation between depression and glycemic control in our sample. Some
data tends to demonstrate a higher prevalence of depression in persons with T2DM when
compared to their diabetes-free counterparts, but the evidence is inconsistent (Hamer,
Batty & Kivimaki, 2011; Fisher et al., 2010). Some longitudinal studies showed that distress
can be linked specifically to diabetes and its management, but neither clinical depression
nor depressive symptoms seem to be associated with glycemic control (Crispin, Robles
& Bernabe, 2015; Hamer, Batty & Kivimaki, 2011). Several factors including biochemical
changes that are directly caused by diabetes, diabetes treatment, or distress associated with
living with this disease has to be studied in order to find an association. Although we did
not find an association between depression and glycemic control, this may be because the
power of our sample (for this particular association) was very low (28%).
Factors significantly associated with poor glycemic control were not associated with
LDL-cholesterol or blood pressure, suggesting that there are different factors that we have
not explored and could be associated.

Limitations and strengths
This study was small and localized to a single hospital in Peru. The small sample size
and single site limits our generalizability and may have limited our scope of findings.
Moreover, patients who participated in the study are representative of a low-income
urban area, so we are unable to generalize the results to the whole population. The socioeconomic characteristics of our population may have influenced rates of adherence,
physical activity, and depression symptoms (Ramos et al., 2014; Popkin, 2001).
Another limitation of this study is that currently, in addition to ADA recommendations, a patient-centered approach is promoted to individualize treatment plans taking
into consideration life expectancy, disease duration, complications, comorbidities, hypoglycemia, and psychological status. Unfortunately, we do not have enough information
to determine the adequate HbA1c level for each participant. Despite this limitation, this
study is important and highlights a challenge to improve the health system for people
with T2DM to achieve a better metabolic control, keeping in mind the necessary focus
on individualization of the intensity of treatment and essential security aspects. Our
findings can help to direct better management of patients with T2DM. We have shown
that patients are not achieving the standards recommended by the ADA and now we
can try to achieve them by targeting the significant factors including: increasing physical
activity, protecting relationships with psychological couple therapy, rechecking diabetes
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medication, and enhancing adherence. Further studies should be conducted to determine
the influence of lifestyle factors in management of T2DM.

Conclusions
The quality of control of HbA1c, LDL-cholesterol, and blood pressure was surprisingly
low in patients with T2DM in this study. In comparison to similar studies, these levels
are the lowest in the literature. Additionally, patients also exhibited low glycemic control.
This situation cannot solely be explained by poor adherence, but it could be explained
in combination with depression or low physical activity. Further studies are needed to
fully understand this problem and until this is achieved, we cannot make the necessary
recommendations to address this problem.
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